Summary
Virobay Inc. (Virobay) is a clinical-stage pharmaceutical company that develops and commercializes novel drugs. The company’s product pipeline includes VBY-129, VBY-376, VBY-825 and multiple candidates. Its VBY-129, is a potent and selective cathepsin S inhibitor to treat neuropathic pain. Virobay’s VBY-376 is an orally-delivered drug for the treatment of nonalcoholic steatohepatitis. The company’s VBY-825 is a potent inhibitor of multiple cathepsins S and B used to treat biliary cirrhosis and NASH. Its multiple candidates serve therapeutic areas such as neuroapathic pain, autoimmune diseases, liver fibrosis, and cancer. The company also provides research and development services. Virobay is headquartered in Menlo Park, California, the US.
Virobay Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Virobay Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Virobay Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Virobay Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Virobay Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Virobay Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9
Virobay Inc., Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Virobay Raises USD8 Million in Extended Series B Financing 10
Virobay Raises US$10 Million In Venture Financing 12
Virobay Raises US$0.3 Million In Venture Financing 13
Licensing Agreements 14
LEO Pharma Enters Into Licensing Agreement With Virobay For Psoriasis Drug 14
Equity Offering 16
Virobay Withdraws IPO for up to USD53.8 Million 16
Virobay Inc. - Key Competitors 18
Key Employees 19
Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21
List of Tables
Virobay Inc., Pharmaceuticals & Healthcare, Key Facts 1
Virobay Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Virobay Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Virobay Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Virobay Inc., Deals By Therapy Area, 2010 to YTD 2016 8
Virobay Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9
Virobay Raises USD8 Million in Extended Series B Financing 10
Virobay Raises US$10 Million In Venture Financing 12
Virobay Raises US$0.3 Million In Venture Financing 13
LEO Pharma Enters Into Licensing Agreement With Virobay For Psoriasis Drug 14
Virobay Withdraws IPO for up to USD53.8 Million 16
Virobay Inc., Key Competitors 18
Virobay Inc., Key Employees 19
Virobay Inc., Other Locations 20
List of Figures
Virobay Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Virobay Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Virobay Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Virobay Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Virobay Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Virobay Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6
Virobay Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Virobay Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8